Selection of aptamers against triple negative breast cancer cells using high throughput sequencing

Abstract Triple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new apta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Débora Ferreira, Joaquim Barbosa, Diana A. Sousa, Cátia Silva, Luís D. R. Melo, Meltem Avci-Adali, Hans P. Wendel, Ligia R. Rodrigues
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6c99aaffdcdf46e9a9583ba91d206a71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c99aaffdcdf46e9a9583ba91d206a71
record_format	dspace
spelling	oai:doaj.org-article:6c99aaffdcdf46e9a9583ba91d206a712021-12-02T13:39:29ZSelection of aptamers against triple negative breast cancer cells using high throughput sequencing10.1038/s41598-021-87998-y2045-2322https://doaj.org/article/6c99aaffdcdf46e9a9583ba91d206a712021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87998-yhttps://doaj.org/toc/2045-2322Abstract Triple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced and the 25 most frequent sequences were aligned for homology within their variable core region, plotted according to their free energy and the key nucleotides possibly involved in the target binding site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells with $$K_{d}$$ K d values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively, were further validated. The binding analysis clearly showed their specificity to MDA-MB-231 cells and suggested the targeting of cell surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is a promising candidate to be used in triple-negative breast cancer treatment and/or diagnosis.Débora FerreiraJoaquim BarbosaDiana A. SousaCátia SilvaLuís D. R. MeloMeltem Avci-AdaliHans P. WendelLigia R. RodriguesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Débora Ferreira Joaquim Barbosa Diana A. Sousa Cátia Silva Luís D. R. Melo Meltem Avci-Adali Hans P. Wendel Ligia R. Rodrigues Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
description	Abstract Triple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced and the 25 most frequent sequences were aligned for homology within their variable core region, plotted according to their free energy and the key nucleotides possibly involved in the target binding site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells with $$K_{d}$$ K d values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively, were further validated. The binding analysis clearly showed their specificity to MDA-MB-231 cells and suggested the targeting of cell surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is a promising candidate to be used in triple-negative breast cancer treatment and/or diagnosis.
format	article
author	Débora Ferreira Joaquim Barbosa Diana A. Sousa Cátia Silva Luís D. R. Melo Meltem Avci-Adali Hans P. Wendel Ligia R. Rodrigues
author_facet	Débora Ferreira Joaquim Barbosa Diana A. Sousa Cátia Silva Luís D. R. Melo Meltem Avci-Adali Hans P. Wendel Ligia R. Rodrigues
author_sort	Débora Ferreira
title	Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
title_short	Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
title_full	Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
title_fullStr	Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
title_full_unstemmed	Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
title_sort	selection of aptamers against triple negative breast cancer cells using high throughput sequencing
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6c99aaffdcdf46e9a9583ba91d206a71
work_keys_str_mv	AT deboraferreira selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT joaquimbarbosa selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT dianaasousa selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT catiasilva selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT luisdrmelo selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT meltemavciadali selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT hanspwendel selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing AT ligiarrodrigues selectionofaptamersagainsttriplenegativebreastcancercellsusinghighthroughputsequencing
_version_	1718392621092569088

Selection of aptamers against triple negative breast cancer cells using high throughput sequencing

Ejemplares similares